TY - JOUR
T1 - Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains
AU - Terzian, Ana C.B.
AU - Azar, Sasha
AU - Estofolete, Cassia F.
AU - Nogueira, Mauricio L.
AU - Vasilakis, Nikos
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/12
Y1 - 2024/12
N2 - Background/Objectives: Yellow fever virus (YFV) (Flaviviridae, Orthoflavivirus) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil). Vaccines produced in the US, France, Senegal, China, and Russia represent 17D-204-derived strains, whereas the Brazilian 17DD has a unique passage/attenuation history from 17D-204-derived strains. Their functional differences in the neutralization profiles are not known. Methods: The Plaque Reduction Neutralization Test (PRNT) was used to determine the neutralization profiles of sera from 209 patients that were previously vaccinated with the 17DD strain against both 17D-204 and 17DD. Results: Sera exhibited significantly more efficient neutralization of 17DD (mean reciprocal PRNT50 183, PRNT80 86, median reciprocal PRNT50 80, and PRNT80 40) compared to 17D-204 (mean reciprocal PRNT50 91, PRNT80 33, median reciprocal PRNT50 40, and PRNT80 10). Conclusions: Our data indicate antigenic differences between 17D and 17DD vaccines.
AB - Background/Objectives: Yellow fever virus (YFV) (Flaviviridae, Orthoflavivirus) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil). Vaccines produced in the US, France, Senegal, China, and Russia represent 17D-204-derived strains, whereas the Brazilian 17DD has a unique passage/attenuation history from 17D-204-derived strains. Their functional differences in the neutralization profiles are not known. Methods: The Plaque Reduction Neutralization Test (PRNT) was used to determine the neutralization profiles of sera from 209 patients that were previously vaccinated with the 17DD strain against both 17D-204 and 17DD. Results: Sera exhibited significantly more efficient neutralization of 17DD (mean reciprocal PRNT50 183, PRNT80 86, median reciprocal PRNT50 80, and PRNT80 40) compared to 17D-204 (mean reciprocal PRNT50 91, PRNT80 33, median reciprocal PRNT50 40, and PRNT80 10). Conclusions: Our data indicate antigenic differences between 17D and 17DD vaccines.
KW - immune response
KW - neutralizing antibodies
KW - vaccine
KW - YFV
UR - http://www.scopus.com/inward/record.url?scp=85213464038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85213464038&partnerID=8YFLogxK
U2 - 10.3390/vaccines12121311
DO - 10.3390/vaccines12121311
M3 - Article
C2 - 39771973
AN - SCOPUS:85213464038
SN - 2076-393X
VL - 12
JO - Vaccines
JF - Vaccines
IS - 12
M1 - 1311
ER -